Discovery of antiviral mechanisms in bats

蝙蝠抗病毒机制的发现

基本信息

  • 批准号:
    8751714
  • 负责人:
  • 金额:
    $ 238.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-09-30 至 2019-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Antiviral interferons provide critical host defense mechanisms against viral infection. In the absence of IFN signaling, the host may be susceptible to lethal viral infection. IFNs protect host cells from viral disease by transcriptionally inducing hundreds of interferon-stimulated genes, which encode a variety of direct antiviral effectors and modulators of host defense signaling pathways. Our recent screening efforts have sought to identify novel human antiviral ISGs, characterize their mechanisms of action, and determine their specificity across a broad range of highly diverse viruses. The viruses of interest include several pathogens that are emerging or re-emerging infectious disease threats. Many of these viruses are transmitted to humans from natural animal reservoirs. Among the numerous reservoir hosts, bats are particularly unique in their ability to harbor highly pathogenic viruses with little to no overt disease. The mechanistic basis for the resistance of bats to viral disease s currently unknown, but several lines of evidence point to a potentially unique innate immune system. The goals of this project are to institute a bat ISG discovery pipeline, with an emphasis on the identification and characterization of novel antiviral mechanisms. Experimentally, we will synthesize a targeted bat ISG library using available bat genomic data. In parallel, we will establish methods for antiviral ISG enrichment from IFN-treated bat cells. Our previous cell-based flow cytometry screening platform will be miniaturized for rapid testing of bat ISGs against numerous viruses in a variety of bat and human cell lines. Follow-up mechanistic studies include the use of molecular virological tools to determine ISG modes of action in the viral life cycle, in addition to biochemical, genetic, and cell biological approaches to uncover th host-based mechanisms of antiviral action.
描述(由申请人提供):抗病毒干扰素提供关键的宿主防御病毒感染的机制。在缺乏IFN信号的情况下,宿主可能易受致命病毒感染。干扰素通过转录诱导保护宿主细胞免受病毒疾病的侵袭

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John W. Schoggins其他文献

Development of a mutant aerosolized ACE2 that neutralizes SARS-CoV-2 emin vivo/em
开发一种在体内中和 SARS-CoV-2 的突变体雾化 ACE2
  • DOI:
    10.1128/mbio.00768-24
  • 发表时间:
    2024-04-29
  • 期刊:
  • 影响因子:
    4.700
  • 作者:
    Daniel L. Kober;Marley C. Caballero Van Dyke;Jennifer L. Eitson;Ian N. Boys;Matthew B. McDougal;Daniel M. Rosenbaum;John W. Schoggins;Peter Palese
  • 通讯作者:
    Peter Palese
A CRISPR screen identifies IFI6 as an ER-resident interferon effector that blocks flavivirus replication
CRISPR 筛选确定 IFI6 为一种阻断黄病毒复制的内质网驻留干扰素效应因子
  • DOI:
    10.1038/s41564-018-0244-1
  • 发表时间:
    2018-09-17
  • 期刊:
  • 影响因子:
    19.400
  • 作者:
    R. Blake Richardson;Maikke B. Ohlson;Jennifer L. Eitson;Ashwani Kumar;Matthew B. McDougal;Ian N. Boys;Katrina B. Mar;Pamela C. De La Cruz-Rivera;Connor Douglas;Genevieve Konopka;Chao Xing;John W. Schoggins
  • 通讯作者:
    John W. Schoggins
Identification of Atovaquone as and Mebendazole as Repurposed Drugs with Antiviral Activity against SARS-CoV-2 (Version 5)
鉴定阿托伐醌和甲苯咪唑为具有抗 SARS-CoV-2 病毒活性的再利用药物(版本 5)
  • DOI:
    10.33774/chemrxiv-2021-b3fv1-v5
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    0
  • 作者:
    M. Ahmed;A. Farag;Ping Wang;Ian N. Boys;Jennifer L. Eitson;Maikke B. Ohlson;Wenchun Fan;Matthew B. McDougal;John W. Schoggins;Hesham A. Sadek
  • 通讯作者:
    Hesham A. Sadek
STT3A-mediated mega protein complex assembly during dengue and Zika virus infection
登革热和寨卡病毒感染期间由STT3A介导的大型蛋白质复合物组装
  • DOI:
    10.1016/j.isci.2025.112535
  • 发表时间:
    2025-06-20
  • 期刊:
  • 影响因子:
    4.100
  • 作者:
    Tao Liu;Natasha W. Hanners;Huangheng Tao;Claudia Szabo;Dao Xu;Wei Lin;John W. Schoggins;Nan Yan;Jianjun Wu
  • 通讯作者:
    Jianjun Wu

John W. Schoggins的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John W. Schoggins', 18)}}的其他基金

Cell intrinsic antiviral mechanisms targeting human enteroviruses
针对人类肠道病毒的细胞内在抗病毒机制
  • 批准号:
    10449724
  • 财政年份:
    2022
  • 资助金额:
    $ 238.5万
  • 项目类别:
Cell intrinsic antiviral mechanisms targeting human enteroviruses
针对人类肠道病毒的细胞内在抗病毒机制
  • 批准号:
    10595616
  • 财政年份:
    2022
  • 资助金额:
    $ 238.5万
  • 项目类别:
A functional evolutionary genetic approach to combat viral infection
对抗病毒感染的功能进化遗传学方法
  • 批准号:
    10664966
  • 财政年份:
    2020
  • 资助金额:
    $ 238.5万
  • 项目类别:
A functional evolutionary genetic approach to combat viral infection
对抗病毒感染的功能进化遗传学方法
  • 批准号:
    10010238
  • 财政年份:
    2020
  • 资助金额:
    $ 238.5万
  • 项目类别:
A functional evolutionary genetic approach to combat viral infection
对抗病毒感染的功能进化遗传学方法
  • 批准号:
    10238787
  • 财政年份:
    2020
  • 资助金额:
    $ 238.5万
  • 项目类别:
A functional evolutionary genetic approach to combat viral infection
对抗病毒感染的功能进化遗传学方法
  • 批准号:
    10468088
  • 财政年份:
    2020
  • 资助金额:
    $ 238.5万
  • 项目类别:
Interactions between type I and III interferon during resolution of HCV infection
I 型和 III 型干扰素在 HCV 感染消退过程中的相互作用
  • 批准号:
    8280675
  • 财政年份:
    2012
  • 资助金额:
    $ 238.5万
  • 项目类别:
Interactions between type I and III interferon during resolution of HCV infection
I 型和 III 型干扰素在 HCV 感染消退过程中的相互作用
  • 批准号:
    8816087
  • 财政年份:
    2012
  • 资助金额:
    $ 238.5万
  • 项目类别:
Interactions between type I and III interferon during resolution of HCV infection
I 型和 III 型干扰素在 HCV 感染消退过程中的相互作用
  • 批准号:
    8639566
  • 财政年份:
    2012
  • 资助金额:
    $ 238.5万
  • 项目类别:
Interactions between type I and III interferon during resolution of HCV infection
I 型和 III 型干扰素在 HCV 感染消退过程中的相互作用
  • 批准号:
    8588413
  • 财政年份:
    2012
  • 资助金额:
    $ 238.5万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 238.5万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 238.5万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 238.5万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 238.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 238.5万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 238.5万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 238.5万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 238.5万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 238.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 238.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了